Serum intact fibroblast growth factor 23 in healthy paediatric population

Stanczyk Malgorzata; Chrul Slawomir; Wyka Krystyna; Tkaczyk Marcin

doi:10.1515/med-2021-0288

Open Medicine (Jul 2021)

Serum intact fibroblast growth factor 23 in healthy paediatric population

Stanczyk Malgorzata,
Chrul Slawomir,
Wyka Krystyna,
Tkaczyk Marcin

Affiliations

Stanczyk Malgorzata: Department of Pediatrics, Immunology and Nephrology, Polish Mother’s Memorial Hospital Research Institute, Rzgowska 281/289, Lodz 93-338, Poland
Chrul Slawomir: Department of Pediatrics, Immunology and Nephrology, Polish Mother’s Memorial Hospital Research Institute, Lodz 93-338, Poland
Wyka Krystyna: Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland
Tkaczyk Marcin: Department of Pediatrics, Immunology and Nephrology, Polish Mother’s Memorial Hospital Research Institute, Lodz 93-338, Poland

DOI: https://doi.org/10.1515/med-2021-0288
Journal volume & issue: Vol. 16, no. 1
pp. 1022 – 1027

Abstract

Read online

It is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent. We present the results of the cross-sectional study concerning FGF23 levels in healthy Polish children.

Published in Open Medicine

ISSN: 2391-5463 (Online)
Publisher: De Gruyter
Country of publisher: Poland
LCC subjects: Medicine
Website: https://www.degruyter.com/journal/key/med/html

About the journal

Abstract

Keywords